Novartis broadens cancer immune therapy pipeline with acquisition, pacts 21.10.2015 13:08 Reuters ZURICH (Reuters) - Novartis has broadened its immuno-oncology pipeline with the acquisition of Admune Therapeutics and through licensing agreements with small drug developers Xoma and Palobiofarma.
